Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of IMCnyeso, HLA- A 0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A 0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

Trial Profile

A Phase I/II Study of IMCnyeso, HLA- A 0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A 0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs IMCnyeso (Primary)
  • Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Synovial sarcoma; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Immunocore
  • Most Recent Events

    • 20 Aug 2018 According to an Immunocore media release, first patient has been dosed in this study. This study is a part of the first program in collaboration of an Immunocore with the GlaxoSmithKline (GSK) for ImmTAC .
    • 16 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 08 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top